Chardan Capital Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA)

Chronological Source Flow
Back

AI Fusion Summary

Tenaya Therapeutics sees mixed analyst ratings: Chardan Capital reiterates buy with an $8 target; Lifesci Capital strong‑buy; others downgrade to sell or lower targets; price objectives range $2–$8.
14/03 07:58 defenseworld.net
2 Πηγές
14/03 08:37 defenseworld.net
Comments
Loading...
0